View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2013	Nov. 08, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	VTUS
Entity Common Stock, Shares Outstanding		20,858,895
Entity Registrant Name	VENTRUS BIOSCIENCES INC
Entity Central Index Key	0001426800
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 32,222,910	$ 20,489,219
Other current assets	134,780	59,584
Total current assets	32,357,690	20,548,803
Computer equipment, net	7,632	6,841
Total assets	32,365,322	20,555,644
Current liabilities:
Accounts payable	2,280,245	1,847,245
Accrued expenses	37,415	898,213
Total current liabilities	2,317,660	2,745,458
Commitments
Stockholders' equity:
Preferred stock, $.001 par value; 5,000,000 shares authorized; 220,000 and 0 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	220	0
Common stock, $.001 par value; 50,000,000 shares authorized; 20,663,301 and 12,934,350 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	20,663	12,934
Additional paid-in capital	135,334,268	110,116,766
Common stock issuable, 125,000 shares at September 30, 2013	368,750	0
Deficit accumulated during the development stage	(105,676,239)	(92,319,514)
Total stockholders’ equity	30,047,662	17,810,186
Total liabilities and stockholders’ equity	$ 32,365,322	$ 20,555,644

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	220,000	0
Preferred stock, shares outstanding	220,000	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	20,663,301	12,934,350
Common stock, shares outstanding	20,663,301	12,934,350
Common stock issuable shares	125,000

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended		96 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating expenses:
Research and development	$ 3,753,319	$ 4,188,127	$ 9,870,871	$ 16,772,777	$ 68,914,278
General and administrative	1,179,689	1,182,176	3,639,863	4,265,889	23,226,264
Loss from operations	(4,933,008)	(5,370,303)	(13,510,734)	(21,038,666)	(92,140,542)
Interest income	51,266	14,906	154,009	39,345	315,129
Interest expense:
Beneficial conversion feature	0	0			(6,001,496)
Amortization of debt discount and warrants	0	0			(2,865,758)
Interest expense	0	0			(4,983,572)
Total other income (expense)	0	0			(13,850,826)
Net loss	$ (4,881,742)	$ (5,355,397)	$ (13,356,725)	$ (20,999,321)	$ (105,676,239)
Basic and diluted net loss per common share (In dollars per share)	$ (0.25)	$ (0.41)	$ (0.71)	$ (1.66)
Weighted average common shares outstanding - basic and diluted (In shares)	19,894,525	12,933,340	18,901,717	12,657,538

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - 9 months ended Sep. 30, 2013 - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-in Capital	Common Stock Issuable	Deficit Accumulated During the Development Stage
Beginning Balance (in shares) at Dec. 31, 2012		12,934,350
Beginning Balance at Dec. 31, 2012	$ 17,810,186	$ 12,934		$ 110,116,766		$ (92,319,514)
Proceeds from the sale of preferred stock sold at $25.00 per share and common stock at $2.50 per share, net of offering costs (in shares)		6,670,000	220,000
Proceeds from the sale of preferred stock sold at$25.00 per share and common stock at $2.50 per share, net of offering costs	20,754,418		$ 6,890	20,747,528		0
Proceeds from the sale of common stock at $3.30 per share, net of offering costs (in shares)		1,058,951
Proceeds from the sale of common stock at $3.30 per share, net of offering costs	3,388,095	$ 1,059		3,387,036
Stock-based compensation to employees and directors for the period from January 1, 2013 to September 30, 2013	935,736			935,736		0
Stock-based payments to consultants for the period from January 1, 2013 to June 30, 2013	29,317			29,317
Common stock issuable for compensation (125,000 shares)	368,750				$ 368,750
Stock-based compensation related to the restricted stock grant	117,885			117,885
Net loss for the period	(13,356,725)					(13,356,725)
Ending Balance at Sep. 30, 2013	$ 30,047,662	$ 20,883		$ 135,334,268	$ 368,750	$ (105,676,239)
Ending Balance (in shares) at Sep. 30, 2013		20,663,301	220,000

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)	9 Months Ended
	Sep. 30, 2013 $ / shares shares
Common stock issuable for compensation (in shares) \| shares	125,000
Issuance During Period 1st
Common Stock issued, per share	$ 2.50
Preferred Stock issued, per share	25.00
Issuance During Period 2nd
Common Stock issued, per share	$ 3.30

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended		96 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (13,356,725)	$ (20,999,321)	$ (105,676,239)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,422,371	2,241,659	10,194,293
Stock-based payments to consultants	29,317	326,313	4,359,576,449
Depreciation	4,375	3,351	39,998
Amortization of deferred financing costs and debt discount		0	3,466,010
Non-cash research and development	0	0	1,087,876
Expenses paid on behalf of the Company satisfied through the issuance of notes	0	0	227,910
Changes in operating assets and liabilities:
Other current assets	(75,196)	(49,055)	(134,780)
Accounts payable and accrued expenses	(427,798)	168,122	2,130,123
Net cash used in operating activities	(12,403,656)	(18,308,931)	(74,221,746)
Cash flows from investing activities:
Purchase of office and computer equipment	(5,166)	(3,240)	(47,630)
Net cash used in investing activities	(5,166)	(3,240)	(47,630)
Cash flows from financing activities:
Net proceeds from sale of common and preferred stock	24,142,513	4,166,494	93,482,174
Proceeds from notes payable	0	0	11,522,380
Proceeds from notes payable to related parties	0	0	5,041,953
Payment for deferred financing costs	0	0	(1,431,603)
Repayment of notes	0	0	(2,719,380)
Repayment of notes payable - related party	0	0	(1,573,000)
Proceeds from exercise of warrants or options	0	730,322	2,169,762
Net cash provided by financing activities	24,142,513	4,896,816	106,492,286
Net increase (decrease) in cash and cash equivalents	11,733,691	(13,415,355)	32,222,910
Beginning of period	20,489,219	36,975,434	0
End of period	32,222,910	23,560,079	32,222,910
Supplemental schedule of non-cash financing activities:
Warrants issued to placement agent	0	0	341,334
Warrants issued to investors in connection with convertible notes	0	0	1,166,989
Notes and accrued interest converted to common stock	0	0	14,003,158
Supplemental disclosure - cash paid for interest	0	0	685,397
Senior Notes 2010 [Member]
Supplemental schedule of non-cash financing activities:
Supplemental disclosure - cash paid for interest	0	0	1,468,254
Related Parties [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock/Warrants issued	0	0	1,255,978
Interest payable		0	266,279
Related Parties [Member] \| Senior Notes 2010 [Member]
Supplemental schedule of non-cash financing activities:
Notes and accrued interest converted to common stock	0	0	3,995,667
Paramount Credit Partners, LLC [Member]
Supplemental schedule of non-cash financing activities:
Debt discount	0	0	782,376
License Agreement [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock/Warrants issued	0	0	414,825
Note Conversion [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock/Warrants issued	0	0	6,001,496
Vendor [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock/Warrants issued		0	5,000
Notes [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Interest payable	$ 0	$ 0	$ 2,139,909

Organization, Business and Basis of Presentation

9 Months Ended

Sep. 30, 2013

Organization, Business and Basis Of Presentation [Abstract]

Organization, Business and Basis of Presentation

Note 1 - Organization, Business and Basis of Presentation:

Organization and business:

Ventrus BioSciences Inc. (“Ventrus” or the “Company”) is a specialty pharmaceutical company primarily focused on the development and commercialization of prescription drugs addressing gastrointestinal problems. Ventrus was incorporated in the State of Delaware on October 7, 2005 (date of inception) and commenced operations in April 2007.

Basis of presentation:

The accompanying condensed balance sheet as of December 31, 2012, which has been derived from the Company’s audited financial statements, and the unaudited interim condensed financial statements, have been prepared in accordance with U.S. generally accepted accounting principles and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information presented not misleading. The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods presented. All such adjustments are of a normal and recurring nature. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed on March 18, 2013. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods.

Capital Resources:

The Company has not derived any revenue from product sales to date as its products have not been approved for sale by the U.S. Food and Drug Administration (“FDA”) or any foreign regulatory agency. Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt. The Company has incurred losses from operations and negative cash flows since inception and expects to continue to incur substantial losses over the next 18 to 24 months as it continues the development and commercialization of its product, diltiazem ("VEN 307") and thereafter if approval is not received or VEN 307 is not successfully launched. As a result, the Company may need to obtain additional funds to finance its operations in the future. In February 2013, the Company raised approximately $20,800,000 in net proceeds in a public offering of its common stock and Series A non-voting convertible preferred stock. In September and October 2013, the Company raised approximately $3,400,000 and $200,000 respectively, in net proceeds under an at-the-market company equity sales program. Management believes the Company currently has sufficient funds to meet its operating requirements and scheduled regulatory and development activities through FDA approval, launch and initial commercialization of diltiazem. Assuming such approval and launch, thereafter, if the Company cannot generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, or other arrangements and it cannot assure such funding will be available on reasonable terms, or at all.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies:

Cash and Cash Equivalents:

All highly liquid investments with maturities of three months or less at the time of purchase are considered to be cash equivalents. All of the Company’s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposit and other accounts, the balances of which, at times and at September 30, 2013, exceed federally insured limits.

Use of estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.

Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.

Stock-based compensation:

The Company’s share-based compensation cost is measured at grant date, using the Black-Scholes option pricing model to estimate the fair value of the award, and is recognized as expense over the employee’s or director’s requisite service period on a straight-line basis. The Company accounts for stock options and warrants granted to non-employees on a fair value basis which is estimated using the Black-Scholes option pricing model. The initial non-cash charge to operations for non-employee options and warrants with vesting are revalued at the end of each reporting period until vested and recognized as consulting expense over the related vesting period.

Research and development:

Research and development expenses include personnel and facility-related expenses, third party contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred. In instances where the Company enters into agreements with third parties for clinical trials, manufacturing and process development, research and other consulting activities, costs are expensed as services are performed. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables.

The Company’s accruals for clinical trials are based on estimates of the services received and pursuant to contracts with the respective clinical trial centers and clinical research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical trial activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received. As such, expense accruals related to clinical trials are recognized based on an estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Income taxes:

The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.

Loss per common share:

Basic net loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Since the Company has only incurred losses, basic and diluted net loss per share is the same. The number of potentially dilutive securities (options, warrants, restricted stock units and preferred stock) excluded from the diluted loss per share calculation for the nine-month periods ended September 30, 2013 and 2012 was 5,594,521, and 3,133,606, respectively.

Commitments

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 3 - Commitments:

Employment agreements:

The Company has employment agreements with the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) which provide for aggregate base salaries of $650,000 per year, a guaranteed bonus of $75,000 per year for the CEO and annual performance-based bonuses of up to 50% and 25%, respectively, of their base salaries. The agreements for the CEO and CFO also provide an incentive bonus of $500,000 for each in the event that the Company’s market capitalization exceeds a specified level. The incentive bonus, if attained, will be paid in a combination of shares of the Company’s common stock worth $300,000 and $200,000 in cash. The number of the shares of common stock each was determined by the closing price of the Company’s common stock as reported on NASDAQ on August 24, 2011 ($9.85), which results in 30,457 shares to be issued to each of the CEO and the CFO. As of September 30, 2013, the market capitalization threshold had not been attained.

The term of both the CEO’s and CFO’s employment agreement end in December 2013. The Board has notified the CEO and CFO that the Board intends to re-new each agreement and is in the process of developing these. It is expected that the new agreements will be in place by the end of December.

Stockholders' Equity

9 Months Ended

Sep. 30, 2013

Stockholders' Transactions [Abstract]

Stockholders’ Equity

Note 4 - Stockholders’ Equity:

Common Stock Transactions:

On January 31, 2012, the Company filed a shelf registration statement with the SEC under which it may offer shares of its common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, in one or more offerings, up to a total dollar amount of $100,000,000. The registration statement became effective as of February 10, 2012. During 2012, the Company raised net proceeds of $4,200,000 from the sale of shares under this registration statement. In February 2013, the Company sold an aggregate of 6,670,000 shares of common stock for $2.50 per share, resulting in net proceeds of approximately $15,600,000, and 220,000 shares of Series A non-voting convertible preferred stock for $25.00 per share, resulting in net proceeds of approximately $5,200,000. In September 2013, the Company raised $3,388,095 in net proceeds under an at-the-market common equity sales program. Pursuant to General Instruction I.B.6. of Form S-3, based on the market value of the Company’s outstanding common stock held by non-affiliates, the Company is only able to use the shelf registration statement up to an amount equal to one-third of the market value of the Company’s outstanding common stock held by non-affiliates less any dollar amount sold under the shelf registration statement in the 12 months prior to the Company’s next sale of securities under the registration statement. As of September 30, 2013, the Company had $18,028,686. of availability under the shelf registration statement pursuant to General Instruction I.B.6. of Form S-3.

Preferred Stock Transactions:

The Series A non-voting convertible preferred shares have a liquidation preference of $0.001 per share and each share of Series A preferred stock is convertible into 10 common shares of the Company’s common stock at any time at the holder’s option.

Common Stock Options and Warrants:

Warrants

In connection with the Company’s financing from 2007 to 2010, the Company issued warrants to investors and/or placement agents to purchase shares of common stock as well as certain consultants.

A summary of the Company’s warrant activity and related information is as follows:

	Nine Months Ended September 30, 2013

		Weighted Average
	Shares	Exercise Price
Outstanding at beginning of period	874,651	$	7.67
Granted	-	$	-
Exercised	-	$	-
Expired	13,605	$	1.24

Outstanding at end of period	861,046	$	7.77
Warrants exercisable at end of period	861,046	$	7.77

All outstanding warrants have vested and no additional expense is expected to be recorded in the future years.

Common Stock

On April 5, 2013, the Company granted restricted stock units to four employees under the 2010 Plan for an aggregate of 500,000 shares of common stock. Of these units, 25% vested immediately at the grant date. The remaining 75% of the units will vest in equal 25% tranches if the 20 trading day volume-weighted average price of our common stock as reported on the NASDAQ Capital Market is at least $4.15, $5.15 and $6.15, respectively. The performance period for the unvested restricted stock units ends on June 30, 2016; if one or more of the stock price thresholds are not met by that date the unvested units will expire. Each employee elected to defer receipt of all shares issuable under the units, including the immediately vested shares, until the earliest of termination of employment, a change in control of Ventrus, or April 1, 2015. The restricted stock units were issued to employees and officers at a price equal to the market price of the Company’s stock at the date of grant. The Company estimated the fair value of the restricted stock units using the Monte Carlo valuation model with the following assumptions; volatility of 56.10% , risk free interest rate of 1.934%, and dividend rate of 0%. The total estimated fair value of the restricted stock units is approximately $1,135,000. Compensation costs for restricted stock award are being recognized on a straight-line basis over the performance period. The first 25% of restricted stock was immediately expensed.

A summary of the status of our restricted stock units as of September 30, 2013 is as follows:

	Nine Months Ended September 30, 2013

			Weighted Average
	Shares		Grant Date Fair Value Per Share
Restricted stock units as of January 1, 2013		0	$	-
Granted April 5, 2013		500,000	$	2.27
Shares vested and issuable		(125,000)	$	2.95

Restricted stock units as of September 30, 2013		375,000	$	2.04

Stock Options

In March 2013, the Company granted options to purchase 30,000 shares under the 2010 Plan to three board members at an exercise price of $3.31 per share.

In May and June 2013, the Company granted options to purchase 125,000 shares and 35,000 shares, respectively, under the 2010 Plan to employees at an exercise price of $2.99 and $2.47, respectively.

In August and September 2013, the Company granted options to purchase 30,000 shares and 60,000 shares, respectively, under the 2010 Plan to employees at an exercise price of $2.51 and $3.15, respectively.

A summary of the Company’s option activity and related information is as follows:

	Nine Months Ended September 30, 2013
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at beginning of period		1,878,475	$	6.72	$	-
Granted		280,000	$	2.94	$	-
Exercised		-		-	$	-
Outstanding at end of period		2,158,475	$	6.23	$	-
Options exercisable at end of period		1,597,449

The Company expects that all but 30,000 outstanding unvested options will vest.

The fair value of the options granted for the nine-month period ended September 30, 2013, was based on the following assumptions:

	2013
Risk-free interest rate		0.33%-1.31	%
Expected volatility		77.01%-77.34	%
Expected life of options		5 years
Expected dividend yield		0	%

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

Calendar Years Ending December 31,	Future Stock Option Compensation Expense
2013 (October through December)	$	278,672
2014		625,436
2015		146,908
2016		99,920
		20,239
Total estimated future stock-based compensation expense – stock options	$	1,171,175

The weighted average remaining contractual life of options outstanding at September 30, 2013 is approximately 7 years.

Stock-based compensation (including payments to consultants) expensed to research and development expense for the nine months ended September 30, 2013 and 2012 was $500,830 and $704,097, respectively. Stock-based compensation (including payments to consultants) expensed to general and administrative expense for the nine months ended September 30, 2013 and 2012 was $950,858 and $1,863,875 respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

License Agreements

9 Months Ended

Sep. 30, 2013

License Arrangement [Abstract]

License Agreements

Note 5 - License Agreements:

Diltiazem (VEN 307) and Phenylepherine (VEN 308)

The Company has an exclusive royalty-bearing license agreement with S.L.A. Pharma, AG (“S.L.A. Pharma”) to sell, make and use diltiazem (VEN 307) for treatment, through topical administration, of fissures and phenylepherine (VEN 308) for treatment, through topical administration, of fecal incontinence (referred to collectively as the “Compound Technologies”) in the United States, Canada and Mexico. In the event that the Compound Technologies are commercialized, Ventrus is obligated to pay to S.L.A. Pharma annual royalties, based upon net sales of the products. In addition, Ventrus is required to make payments to S.L.A. Pharma up to an aggregate amount of $20 million upon the achievement of various milestones related to regulatory events. On October 9, 2012, Ventrus made a milestone payment of $125,000 to S.L.A. Pharma which was due upon Investigational Review Board approval of a Phase III study of a licensed product incorporating VEN 307.

Should Ventrus make any improvements regarding the Compound Technologies, Ventrus is required to grant S.L.A. Pharma licenses to use such improvements.

As compensation for S.L.A. Pharma’s participation in the management and the development of the Compound Technologies, Ventrus is required to make separate payments to S.L.A. Pharma equal to $41,500 per month for each of diltiazem and phenylephrine. Per the agreement, Ventrus’ obligation to make these monthly payments was to terminate upon a new drug application (“NDA”) filing. Pursuant to amendments to the license agreement, the Company, as of September 30, 2010, was no longer required to make the $41,500 monthly payments for phenylephrine. Management anticipates the $41,500 per month management fee for diltiazem will cease by the end of 2013.

Ventrus is also required to reimburse S.L.A. Pharma for clinical development costs associated with the technology development of both diltiazem and phenylephrine. Ventrus’ total payment obligation for the diltiazem project was limited to $4,200,000, and these payments were made from August 2007 through December 31, 2011. On June 6, 2011, Ventrus further amended the Exclusive License Agreement with S.L.A. Pharma. The amendment added additional services outside the scope of the agreement for which Ventrus was required to pay S.L.A. Pharma $400,000. The report generated by these services was provided by S.L.A. Pharma during the first quarter of 2013 and Ventrus made the payment in February 2013. S.L.A. Pharma has been paid an additional $600,000 for services for the phenylephrine project through September 30, 2013. S.L.A. Pharma did not provide Ventrus with any services for the phenylephrine project in 2011 and 2012, and management does not expect any services from S.L.A. Pharma for the phenylephrine project in the foreseeable future.

As of September 30, 2013, Ventrus’ does not expect to pay S.L.A. Pharma additional development costs.

Iferanserin (VEN 309)

In March 2008, Ventrus entered into an exclusive worldwide license agreement with Sam Amer & Co., Inc. (“Amer”) whereby Ventrus acquired certain patent rights to iferanserin (VEN 309) for the topical treatment of any anorectal disorders. On June 5, 2011, the Company entered into an agreement with Amer to acquire all rights, title and interest to iferanserin, which acquisition closed on November 14, 2011. On June 25, 2012, based on the results of the Phase III clinical trial, the Company ceased all research and development activity related to iferanserin and therefore does not expect any additional development costs.

New Product Candidates

On November 8, 2013, Ventrus entered into a License and Collaboration Agreement with Therabiome, LLC, for all intellectual property and know-how owned or controlled by Therabiome relating to the oral delivery of pharmaceutical drugs to specific sites in the intestine, using a pH sensitive controlled release platform technology. Under the agreement, Therabiome granted to Ventrus the exclusive worldwide license, with rights to sublicense, to develop the intellectual property for commercialization (a) in the use of bacteria, viruses, proteins and small molecules by oral delivery in (i) gastro-intestinal dysbiosis, including but not limited to C. difficile, irritable bowel syndrome-constipation and inflammatory bowel disease, (ii) auto-immune disorders and autism, including but not limited to as controlled by bacteria or virus, and (iii) orally delivered vaccines, including viral and bacterial, and (b) any oral delivery of small molecules using the licensed intellectual property. Ventrus will be solely responsible for all research and development activities with respect to any product it develops under the license.

For the license, Ventrus paid Therabiome an upfront non-refundable license fee of $300,000. Ventrus must pay Therabiome clinical and regulatory milestones for each product or therapy advanced from the platform for U.S. regulatory milestones. Ventrus also must pay Therabiome lesser amounts for foreign regulatory milestones, which vary by country and region. Ventrus also must pay Therabiome royalties on annual net sales of a product in the low to mid-single digit percentages plus, once annual net sales exceed two certain thresholds, a one-time cash payment upon reaching each threshold.

Therabiome must pay Ventrus royalties on annual net sales of any product it develops, using the intellectual property, in the low double to mid-double percentages, depending on the level of development or involvement Ventrus had in the product.

Legal Proceedings

9 Months Ended

Sep. 30, 2013

Legal Matter Disclosure [Abstract]

Legal Proceedings

Note 6 - Legal Proceedings:

In June 2012, the Company announced that is product iferanserin (VEN 309), failed to meet its end point at the completion of its Phase III clinical trial. In May 2013 two purported class action lawsuits alleging violations of the federal securities laws were filed in New York against the Company, two of its executive officers and the lead underwriter of its initial public offering. The lawsuits include allegations that, during the class period between December 17, 2010 and June 25, 2012, the Company and its executive officers and underwriter made various statements related to the Company’s product, iferanserin (VEN 309), including but not limited to, the market for the product, the potential competitors, and the results of clinical trials, thereby inflating the price of our common stock. The complaints seek unspecified damages, interest, attorneys’ fees, and other costs. On July 23, 2013, the Court consolidated the actions and appointed lead plaintiffs and lead counsel. On September 16, 2013, lead plaintiffs filed a consolidated amended complaint. The Company and its officers intend to vigorously defend against these claims to seek dismissal of the consolidated complaint. Due to the early stage of these proceedings, the Company is unable to predict the outcome or reasonably estimate a range of possible loss relating to these claims.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Cash and Cash Equivalents

Cash and Cash Equivalents:

Use of estimates

Use of estimates:

Stock-based compensation

Stock-based compensation:

Research and development

Research and development:

Income taxes

Income taxes:

Loss per common share

Loss per common share:

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of Restricted Stock Units

A summary of the status of our restricted stock units as of September 30, 2013 is as follows:

	Nine Months Ended September 30, 2013

			Weighted Average
	Shares		Grant Date Fair Value Per Share
Restricted stock units as of January 1, 2013		0	$	-
Granted April 5, 2013		500,000	$	2.27
Shares vested and issuable		(125,000)	$	2.95

Restricted stock units as of September 30, 2013		375,000	$	2.04

Assumptions for Weighted Average Fair Value of Options Granted

The fair value of the options granted for the nine-month period ended September 30, 2013, was based on the following assumptions:

	2013
Risk-free interest rate		0.33%-1.31	%
Expected volatility		77.01%-77.34	%
Expected life of options		5 years
Expected dividend yield		0	%

Estimated Future Stock Based Expenses Relating to Unvested Stock Options

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

Calendar Years Ending December 31,	Future Stock Option Compensation Expense
2013 (October through December)	$	278,672
2014		625,436
2015		146,908
2016		99,920
		20,239

Total estimated future stock-based compensation expense – stock options	$	1,171,175

Stock Option [Member]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s option activity and related information is as follows:

	Nine Months Ended September 30, 2013
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at beginning of period		1,878,475	$	6.72	$	-
Granted		280,000	$	2.94	$	-
Exercised		-		-	$	-

Outstanding at end of period		2,158,475	$	6.23	$	-
Options exercisable at end of period		1,597,449

Warrant [Member]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s warrant activity and related information is as follows:

	Nine Months Ended September 30, 2013

		Weighted Average
	Shares	Exercise Price
Outstanding at beginning of period	874,651	$	7.67
Granted	-	$	-
Exercised	-	$	-
Expired	13,605	$	1.24

Outstanding at end of period	861,046	$	7.77
Warrants exercisable at end of period	861,046	$	7.77

Organization, Business and Basis of Presentation - Additional Information (Details) - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	Oct. 31, 2013	Feb. 28, 2013	Sep. 30, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Entity Incorporation Date Of Incorporation			Oct. 07, 2005
Entity Incorporation State Country Name			Delaware
Net proceeds raised from common stock issued in a public offering		$ 20,800,000		$ 4,200,000
Proceeds From The Sale Of Common Stock At Net Of Offering Costs			$ 3,388,095
Equity Sales Programme [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Proceeds From The Sale Of Common Stock At Net Of Offering Costs			$ 3,400,000
Subsequent Event [Member] \| Equity Sales Programme [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Proceeds From The Sale Of Common Stock At Net Of Offering Costs	$ 200,000

Summary of Significant Accounting Policies - Additional Information (Details) - shares	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Significant Accounting Policies [Line Items]
Potentially dilutive securities excluded from diluted loss per share calculation	5,594,521	3,133,606

Commitments - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 24, 2011	Sep. 30, 2013
Commitments and Contingencies Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Distributions Paid	$ 200,000
Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense	$ 300,000
Common stock closing price	$ 9.85
Second Threshold [Member]
Commitments and Contingencies Disclosure [Line Items]
Expected bonus, shares	30,457
Chief Executive Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary		$ 650,000
Guaranteed bonus		75,000
Incentive Bonus		$ 500,000
Chief Executive Officer [Member] \| Maximum [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual performance-based bonus, percentage		50.00%
Chief Financial Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary		$ 650,000
Incentive Bonus		$ 500,000
Chief Financial Officer [Member] \| Maximum [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual performance-based bonus, percentage		25.00%

Stockholders' Equity - Additional Information (Details) - USD ($)		1 Months Ended						9 Months Ended		12 Months Ended
	Apr. 05, 2013	Jun. 30, 2013	May 31, 2013	Mar. 31, 2013	Feb. 28, 2013	Jan. 31, 2012	Aug. 24, 2011	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Stockholders Equity Note [Line Items]
Net proceeds raised from common stock issued in a public offering					$ 20,800,000					$ 4,200,000
Stock option, weighted average remaining contractual life								7 years
Outstanding unvested options								30,000
Common Stock issued, per share					$ 2.50
Common stock, shares issued					6,670,000			20,663,301		12,934,350
Preferred Stock, Conversion Basis								Series A preferred stock is convertible into 10 common shares of the Company’s common stock at any time at the holder’s option
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total								$ 1,135,000
Restricted Stock Expensed Percentage								25.00%
Proceeds From The Sale Of Common Stock At Net Of Offering Costs								$ 3,388,095
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs								$ 18,028,686
Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Proceeds from the sale of preferred stock sold at $25.00 per share and common stock at $2.50 per share, net of offering costs (in shares)								220,000
Additional Paid-in Capital [Member]
Stockholders Equity Note [Line Items]
Common Stock issued					$ 15,600,000
Proceeds From The Sale Of Common Stock At Net Of Offering Costs								$ 3,387,036
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Proceeds from the sale of preferred stock sold at $25.00 per share and common stock at $2.50 per share, net of offering costs (in shares)					220,000
Net proceeds from series A non-voting convertible preferred stock					$ 5,200,000
Public offer net price per share					$ 25.00
Preferred Stock, Liquidation Preference Per Share								$ 0.001
Maximum [Member]
Stockholders Equity Note [Line Items]
Net proceeds raised from common stock issued in a public offering						$ 100,000,000
Fair Value Assumptions, Risk Free Interest Rate								1.31%
Minimum [Member]
Stockholders Equity Note [Line Items]
Fair Value Assumptions, Risk Free Interest Rate								0.33%
Research and Development Expense [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense								$ 500,830	$ 704,097
General and Administrative Expenses [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense								$ 950,858	$ 1,863,875
Equity Incentive Plan 2010 [Member]
Stockholders Equity Note [Line Items]
Stock options granted		35,000	125,000				30,000	60,000
Option granted exercise price		$ 2.47	$ 2.99				$ 2.51	$ 3.15
Equity Incentive Plan 2010 [Member] \| One Director [Member]
Stockholders Equity Note [Line Items]
Option granted exercise price				$ 3.31
Equity Incentive Plan 2010 [Member] \| Three Directors [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				30,000
Restricted Stock Units (RSUs) [Member]
Stockholders Equity Note [Line Items]
Percentage Of Restricted Stock Units Vested Descriptions	25% vested immediately at the grant date. The remaining 75% of the units will vest in equal 25% tranches if the 20 trading day volume-weighted average price of our common stock as reported on the NASDAQ Capital Market is at least $4.15, $5.15 and $6.15, respectively.
Fair Value Assumptions, Expected Volatility Rate								56.10%
Fair Value Assumptions, Risk Free Interest Rate								1.934%
Fair Value Assumptions, Expected Dividend Rate								0.00%
Restricted Stock Units (RSUs) [Member] \| Four Employees [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	500,000

Warrant Activity and Related Information (Details)	9 Months Ended
Warrant Activity and Related Information (Details)	Sep. 30, 2013 $ / shares shares
Shares
Warrant, Outstanding at beginning of period \| shares	874,651
Warrant, Granted \| shares	0
Warrant, Exercised \| shares	0
Warrant, Expired \| shares	13,605
Warrant, Outstanding at end of period \| shares	861,046
Warrants exercisable at end of period \| shares	861,046
Weighted Average Exercise Price
Warrant, Outstanding at beginning of period \| $ / shares	$ 7.67
Warrant, Granted \| $ / shares	0
Warrant, Exercised \| $ / shares	0
Warrant, Expired \| $ / shares	1.24
Warrant, Outstanding at end of period \| $ / shares	7.77
Warrants exercisable at end of period \| $ / shares	$ 7.77

Common Stock Restricted Stock Units (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2013 $ / shares shares
Stockholders Equity Note [Line Items]
Common Stock Shares,Restricted stock units as of January 1, 2013 \| shares	0
Common Stock Shares, Granted April 5, 2013 \| shares	500,000
Common Stock Shares, Shares vested and issuable \| shares	(125,000)
Common Stock Shares,Restricted stock units as of September 30, 2013 \| shares	375,000
Weighted Average Grant Date Fair Value Per Share, Restricted stock units as of January 1, 2013 \| $ / shares	$ 0
Weighted Average Grant Date Fair Value Per Share, Granted April 5, 2013 \| $ / shares	2.27
Weighted Average Grant Date Fair Value Per Share, Shares vested and issuable \| $ / shares	2.95
Weighted Average Grant Date Fair Value Per Share, Restricted stock units as of September 30, 2013 \| $ / shares	$ 2.04

Option Activity and Related Information (Details)	9 Months Ended
Option Activity and Related Information (Details)	Sep. 30, 2013 USD ($) $ / shares shares
Shares
Option, Outstanding at beginning of period \| shares	1,878,475
Option, Granted \| shares	280,000
Options, Exercised \| shares	0
Option, Outstanding at end of period \| shares	2,158,475
Options exercisable at end of period \| shares	1,597,449
Weighted Average Exercise Price
Option, Outstanding at beginning of period \| $ / shares	$ 6.72
Option, Granted \| $ / shares	2.94
Option, Exercised \| $ / shares	0
Option, Outstanding at end of period \| $ / shares	$ 6.23
Aggregate Intrinsic Value
Option, Outstanding at beginning of period \| $	$ 0
Option, Granted \| $ / shares	$ 0
Option, Exercised \| $	$ 0
Option, Outstanding at end of period \| $	$ 0

Assumptions for Fair Value of Options Granted (Details)	9 Months Ended
Assumptions for Fair Value of Options Granted (Details)	Sep. 30, 2013
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected life of options	5 years
Expected dividend yield	0.00%
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Risk-free interest rate	1.31%
Expected volatility	77.34%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Risk-free interest rate	0.33%
Expected volatility	77.01%

Estimated Future Stock-Based Compensation Expense Relating to Unvested Stock Options (Details)	Sep. 30, 2013 USD ($)
Stockholders Equity Note [Line Items]
2013 (October through December)	$ 278,672
2014	625,436
2015	146,908
2016	99,920
Total	20,239
Total estimated future stock-based compensation expense - stock options	$ 1,171,175

License Agreements - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2013	Oct. 09, 2012	Aug. 31, 2007
Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment For Nonrefundable License Fee	$ 300,000
Sl Pharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payment			$ 20,000,000
Additional services agreement amount			400,000
Sl Pharma [Member] \| License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payment		$ 125,000
Diltiazem Project [Member] \| License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development costs	$ 41,500
S.L.A. Pharma [Member] \| Diltiazem Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License agreement, monthly payments			41,500
S.L.A. Pharma [Member] \| Diltiazem Project [Member] \| Maximum [Member] \| License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total payment obligation under agreement			4,200,000
S.L.A. Pharma [Member] \| Phenylephrine Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Additional services agreement amount			600,000
License agreement, monthly payments			$ 41,500